Business Wire

CA-OMNICELL

4.1.2021 14:02:10 CET | Business Wire | Press release

Share
Omnicell to Partner with Guy’s and St Thomas’ NHS Foundation Trust, London on Development of European Technology-Enabled Intelligence Centre as Part of Expansion of Omnicell Systems Across the South East London NHS Integrated Care System

Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management and supply chain solutions for health systems, today announced its intent to enter a new partnership with Guy’s and St Thomas’ NHS Foundation Trust, London to develop technology-enabled inventory optimization and intelligence services.

As part of a £10.5 million capital investment, the South East London Integrated Care System (ICS) will expand the deployment of Omnicell automation systems across six acute hospital sites. This also includes the opportunity for Omnicell and the Trust to launch a European-based technology-enabled intelligence center with the aim to deliver advanced analytics to manage supplies and medications. Combined with the expansion of Omnicell automated dispensing systems across the South East London hospitals, it is expected that this technology-enabled intelligence center will provide a high level of visibility and actionable insights for the South East London Integrated Care System to improve efficiency and patient safety.

The Integrated Care System includes two of the UK’s biggest hospital trusts, Guy’s and St Thomas’ NHS Foundation Trust and Kings College Hospital NHS Foundation Trust, as well as Lewisham and Greenwich NHS Trust. These Trusts are already using a mix of Omnicell’s XT supply and medication dispensing systems to manage clinical inventory and medications. The ICS successfully secured capital funding from the Department of Health Wave IV Estate Transformation Fund to undertake a regional supply chain transformation program.

By choosing Omnicell as its sole Inventory Management Solution, the Integrated Care System will be able to deliver consistency of practice and openly share data through a single instance based in the cloud. These systems, coupled with the expected technology-enabled intelligence centre based at Guy’s and St Thomas’, aim to provide total visibility of all medication and clinical inventory across the region. The solution will leverage the latest AI tools to provide real-time analytic support and system optimization. This will help reduce the risk of dispensing errors and help deliver the right medication, in the right place, at the right time.

Omnicell’s cloud-based intelligence, automation, and technology-enabled services are helping health systems across the globe to:

  • support patient safety
  • drive efficiencies
  • reduce unnecessary and costly wastage
  • allow healthcare professionals to increase their time for face-to-face patient care.

David Lawson, Chief Procurement Officer for Guy’s and St Thomas’, said: “We are delighted to join with Omnicell to bring this cutting-edge solution to the UK. The Trust has successfully deployed Omnicell systems for supplies and medication for over 10 years and the opportunity of this new intelligence offering alongside the expansion of Omnicell systems across South East London represents the next chapter in a successful long term partnership with Omnicell. Through this collaboration, South East London hopes to develop new AI tools to reduce variation between hospital sites and optimize system performance to allow for improved patient outcomes and operational efficiency at a regional level.”

Sara Dalmasso, vice president and general manager, International, at Omnicell said: “Expanding technology-enabled services and intelligence solutions reflects our ambition to deploy advanced analytic and optimization tools to support health systems across Europe. This new partnership with Guy’s and St Thomas’ also demonstrates that Omnicell is quickly becoming the go-to provider for regional medication and supply management solutions across the UK. We are hugely excited to be offered another opportunity to work with a likeminded partner who wants to reshape how automated inventory and medical supply management systems are viewed in the NHS and the wider European market. We share a goal of improving healthcare and patient safety, and I’m looking forward to working with Guy’s and St Thomas’ and South East London to support our joint vision.”

About Guy’s and St Thomas’ and South East London Integrated Care System

Guy’s and St Thomas’ provides 2.6 million patient contacts in acute and specialist hospital services and community services every year. As one of the biggest NHS trusts in the UK, with an annual turnover of almost £1.7 billion, we employ around 18,000 staff. To learn more, visit: www.guysandstthomas.nhs.uk

South East London Integrated Care System brings together local health and care organisations and local councils to re-design care and improve population health through shared leadership and collective action. It covers six London boroughs, Bexley, Bromley, Greenwich, Lambeth, Lewisham and Southwark, with 1.9 million patients. Priorities include reducing costs through provider collaboration and changing the way they work together to deliver transformation. To learn more, visit: https://www.ourhealthiersel.nhs.uk/

About Omnicell

Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Over 7,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. More than 50,000 institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. To learn more, visit www.omnicell.com .

OMCL-G

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NetApp Completes Acquisition of PEAK:AIO to Accelerate Zettabyte-scale AI Deployments2.11.2026 14:00:00 CET | Press release

Acquisition strengthens NetApp Novus, high-performance storage, with differentiated metadata technology and a parallel file architecture purpose-built for AI NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that it completed the acquisition of PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. With this acquisition, NetApp can leverage metadata services and parallel namespace innovations to power the fastest storage on the planet, NetApp Novus, to support zettabyte-scale file systems for the most demanding workloads of AI clouds and GPU-as-a-service providers. For the best AI infrastructure economics, organizations need to keep GPU resources continuously supplied with data without bottlenecks. The acquisition advances NetApp’s strategy for the next phase of AI infrastructure by bringing PEAK:AIO’s metadata and parallel file system expertise together with NetApp ONTAP, giving customers a path to AI

Bentley Systems Announces Seequent’s Acquisition of Seismic Interpretation Software Company Eliis2.11.2026 14:00:00 CET | Press release

Strengthens Seequent’s subsurface software portfolio, energy and geophysics capabilities, and expands team of specialists Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced that Seequent, The Bentley Subsurface Company, has acquired seismic interpretation software company Eliis. The acquisition will enrich Seequent’s capabilities in geophysics with seismic data interpretation and further advance subsurface understanding to help solve complex global challenges. Eliis’ global team of more than 100 geoscientists, technical specialists, and researchers will join Seequent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029964674/en/ 3D view from PaleoScan showcasing recent advancements in seismic interpretation workflows that support prospect evaluation and exploration decision-making Founded in 2007 and with headquarters in Montpellier, France, Eliis develops advanced

HistoSonics Receives Regulatory Approval in Singapore, Advancing Expansion Across Asia-Pacific2.11.2026 14:00:00 CET | Press release

HistoSonics today announced that the company has received market authorization from Singapore’s Health Sciences Authority (HSA) for its Edison® Histotripsy System (under the device name HistoSonics Histotripsy System), marking another significant milestone in the company’s continued international expansion and creating new opportunities to advance access to histotripsy throughout the Asia-Pacific region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102090757/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image-guided platform that uses the mechanical properties of focused ultrasound, known as histotripsy, to mechanically destroy and liquefy unwanted tissue and tumors. The technology offers a fundamentally new approach to tissue destruction without the need for invasive procedures, radiation, or thermal energy. The Edison System is currently authorized for the destruction of liver

NIQ Publishes 2026 ESG Progress Report, Highlighting Action Across Climate, People, Communities, and Responsible AI2.11.2026 12:45:00 CET | Press release

Report details NIQ’s continued focus on responsible business, including its first climate risk assessment, expanded employee development and more than 100,000 volunteer hours NIQ (NYSE: NIQ), a leading consumer intelligence company, today released its 2026 Environmental, Social and Governance (ESG) Progress Report, detailing the company’s progress on key ESG priorities throughout 2025. The report covers NIQ’s efforts across environmental responsibility, its people and communities, data integrity, and responsible AI. Key highlights from 2025 include:Strengthened its approach to climate risk and environmental measurement: NIQ conducted its first climate risk assessment aligned with Task Force on Climate-related Financial Disclosures (TCFD) recommendations, tracked Scope 1, 2 and 3 emissions under the GHG Protocol, and externally verified its carbon footprint. Invested in associate development, engagement and well-being: Internal mobility increased to 35%, up from 30%, while performance r

Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer2.11.2026 12:42:00 CET | Press release

In pMMR/MSS colon cancer, neoadjuvant BOT+BAL met the trial’s primary endpoint with a 36% major pathologic response rate, including 29% pathologic complete response, within an overall 71% pathologic response rate after one BOT dose and two BAL dosesNo patients treated with BOT+BAL had their cancer return, with median follow-up of 19.2 months in MSS disease and 16.7 months in MSI-H disease; 12-month event-free survival was 100% in both combination cohorts.Independent, multicenter UNICORN findings reinforce the NEST peer-reviewed neoadjuvant evidence supporting Agenus’ planned Phase 3 ROBBIN trial in curative-intent MSS/pMMR colon cancer Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of results from the investigator-sponsored, multicenter Phase 2 UNICORN trial evaluating short-course preoperative, or neoadjuvant, botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, alone or in combination with ba

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye